Human CMKLR1 activation kit by CRISPRa

CAT#: GA100875

CMKLR1 CRISPRa kit - CRISPR gene activation of human chemerin chemokine-like receptor 1



  See Other Versions

CNY 12255.00


货期*
4周

规格
    • 1 kit

Product images

推荐一起购买 (3)
Rabbit Polyclonal Anti-CMKLR1 Antibody
    • 100 ul

CNY 1999.00
CNY 3280.00


CMKLR1 (Myc-DDK-tagged)-Human chemokine-like receptor 1 (CMKLR1), transcript variant 2
    • 10 ug

CNY 3656.00
CNY 4370.00


CMKLR1 Rabbit polyclonal Antibody
    • 100 ul

CNY 1999.00
CNY 3280.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol CMKLR1
Locus ID 1240
Kit Components

GA100875G1, CMKLR1 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA100875G2, CMKLR1 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA100875G3, CMKLR1 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Reference Data
RefSeq NM_001142343, NM_001142344, NM_001142345, NM_004072
Synonyms CHEMERINR; ChemR23; DEZ; RVER1
Summary Receptor for the chemoattractant adipokine chemerin/RARRES2 and for the omega-3 fatty acid derived molecule resolvin E1. Interaction with RARRES2 induces activation of intracellular signaling molecules, such as SKY, MAPK1/3 (ERK1/2), MAPK14/P38MAPK and PI3K leading to multifunctional effects, like, reduction of immune responses, enhancing of adipogenesis and angionesis. Resolvin E1 down-regulates cytokine production in macrophages by reducing the activation of MAPK1/3 (ERK1/2) and NF-kappa-B. Positively regulates adipogenesis and adipocyte metabolism. Acts as a coreceptor for several SIV strains (SIVMAC316, SIVMAC239, SIVMACL7E-FR and SIVSM62A), as well as a primary HIV-1 strain (92UG024-2).[UniProtKB/Swiss-Prot Function]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...